Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy



Survival: 20.5 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: Italy
   
City/State/Province: Milan
   
Hospital: Fondazione IRCCS Istituto Nazionale dei Tumori
   
Journal: Link
   
Date: 12/2010

Description:
Patients:
This study involved 20 previously untreated metastatic melanoma patients with a median age of 54 years (range of 22-75). Sixty (60) percent of the patients were male.

Treatment:
Patients were given a combination of the biologic therapy bevacizumab (an antibody the blocks a protein involved in cancer cell growth) and the chemotherapy agent fotemustine as a first-line treatment.

Toxicity:
The maximum toxicity level reported was of grade 4. Grade 3-4 neutropenia was reported by 50% of the patients and 20% had grade 3-4 hypertension. There was also one case each of pulmonary embolism, serious shortness of breath, and uterine bleeding.

Results:
The reported median overall survival was 20.5 months.

Support:
One of the authors is employed by Roche, makers of bevacizumab.

Correspondence: Dr. Andrea Anichini; email: andrea.anichini@istitutotumori.mi.it

E-mail to a Friend Email Physician More Information